Flora Growth Corp. 8-K

What Happened Flora Growth Corp. (FLGC) filed an 8-K reporting that on January 6, 2026 the Board unanimously approved by written consent the appointment of Larry Zeifman as a director and as Chair of the Audit Committee. Mr. Zeifman was also named a member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee. The Board also appointed Manfred Leventhal as Chair of the Nominating Committee. The Board determined Mr. Zeifman is an independent director and meets Nasdaq and SEC Rule 10A-3 standards for Audit Committee service.

Key Details

• Appointment date: January 6, 2026 (Board action by unanimous written consent).
• Roles for Larry Zeifman: Director; Chair of the Audit Committee; member of Audit, Compensation and Nominating Committees.
• Governance findings: Board determined Zeifman is independent and qualifies under Nasdaq rules and Rule 10A-3.
• Vacancy filled: Zeifman’s appointment fills the vacancy caused by the passing of Harold Wolkin on August 25, 2025.
• No arrangements or related-party interests: Filing states there are no agreements, family relationships, or reportable transactions between Zeifman and the Company, and no compensation grants tied to his appointment as of the report.

Why It Matters This change fills a board vacancy and places an independent director as Audit Committee Chair, which is important for financial oversight and compliance with Nasdaq/SEC committee standards. For investors, the filing indicates the company strengthened its governance structure without disclosing any special compensation or related-party arrangements tied to the appointment, suggesting no immediate material financial impact from the change.